title: Bioequivalence of two oral cyclosporine preparations.
abstract: A comparison of bioequivalence of two cyclosporine (CAS 59865-13-3) preparations was performed. Ten cyclosporine treated patients with transplanted kidneys were included. Criteria were successful transplantation and minimum period from transplantation of at least 6 months. Two months before the experiment, cyclosporine concentrations had to be in therapeutic range without significant oscillation, and kidney function stabile. There had to be no signs of cyclosporine nephrotoxicity. During the objective biochemical analysis it was not allowed to find malfunction in any of the patient's organ important for cyclosporine pharmacokinetics. Cyclosporine concentrations in whole blood were measured with a specific fluoroimmunoassay. Cyclosporine and metabolites concentrations were measured with radioimmunoassay with non-specific antibody. Mean value and standard deviations and shape of distribution were calculated for all numeric data of patients, measured biochemical and other laboratory parameters. Variance analysis for all measured cyclosporine concentrations according to sampling times (C0 to C12, maximal concentrations C(M), time to maximal concentrations t(M), times of absorption delaying t(Lag) and area under the measured concentration curves (AUC) were statistically checked. According to these data it is concluded that the preparations are bioequivalent; a time to reach maximum concentration was slightly shorter for test preparation (2.5 and 3.2 h, respectively), but not statistically significant. There are no significant differences between the areas under the concentration curves (1667 and 1665 ng.h/ml, respectively). After the calculation of pharmacokinetic parameters of concentration data measured by a non-specific method a significant difference for areas under concentration curves was seen (3709 and 4600 ng.h/ml, respectively).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Center for Biomedical Research, Clinical Hospital Center Zagreb, Croatia.
authors.forename: F
authors.initials: F
authors.lastname: Plavsic
authors.forename: A
authors.initials: A
authors.lastname: Wolf-Coporda
authors.forename: M
authors.initials: M
authors.lastname: Bilusić
authors.forename: Z
authors.initials: Z
authors.lastname: Lovrić
authors.forename: V
authors.initials: V
authors.lastname: Macolić
authors.forename: Z
authors.initials: Z
authors.lastname: Puretić
authors.forename: L
authors.initials: L
authors.lastname: Bubić-Filipi
authors.forename: B
authors.initials: B
authors.lastname: Vrhovac
mesh_terms: D000328:Adult; D018592:Cross-Over Studies; D016572:Cyclosporine / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D005260:Female; D015200:Fluoroimmunoassay; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology; D008297:Male; D011863:Radioimmunoassay; D013810:Therapeutic Equivalency
chemical_list: D016572:Cyclosporine